Project Grant R01HL180531
Award Date
8/1/25
Completion Date
5/31/29
Dollars Obligated
$729K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,193,262 to The Regents of the University of California, San Francisco to develop an adeno-associated virus-mediated SGPL1 gene therapy as a potential first-in-class treatment for idiopathic pulmonary fibrosis (IPF). The research aims to confirm the efficacy of this gene therapy in reducing lung fibrosis and downstream profibrotic signaling in mouse models and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research provides $695,421 to The Regents of the University of California, San Francisco (UCSF) to conduct research focused on reversing pathogenic remodeling in idiopathic pulmonary fibrosis (IPF). The key objectives are to define pro-reparative differentiation pathways in the fibroblast and stem cell compartments that can be leveraged as therapy, and...
This federal Project Grant award of $683,564 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research focused on understanding the contribution of aberrant alveolar epithelial cells to the development and progression of pulmonary fibrosis. The 5-year award to The Trustees of the University of Pennsylvania, which began on Jul 1, 2025, will investigate how stress signaling through the PERK-ISR pathway impacts the emergence and...
This R01 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $596,179 over a 5-year period beginning on January 1, 2025 to conduct research on the role of macropinocytosis, a cellular process, in the development of pulmonary fibrosis. The research aims to determine whether inhibiting macropinocytosis can attenuate fibrosis in animal models and cell culture systems, as well as elucidate the molecular mechanisms by...
This $1,546,880 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the regulatory mechanisms governing myofibroblast differentiation in idiopathic pulmonary fibrosis (IPF). The primary objectives are to: 1) determine the "regulatory architecture" of open chromatin in myofibroblasts in IPF, 2) examine how expression levels of E-box transcription factors...
This Project Grant award of $325,080 from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) supports research to investigate the role of aging and metabolic dysfunction in disrupting alveolar epithelial progenitor cell function in pulmonary fibrosis. The funded project will utilize an aged mouse model of idiopathic pulmonary fibrosis (IPF) to characterize the impact of aging on mitochondrial quality control and metabolic changes in...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,410,668 to The Methodist Hospital Research Institute (HMRI) to investigate the role of cyclin-dependent kinase 9 (CDK9) in the pathogenesis and treatment of idiopathic pulmonary fibrosis (IPF). The research aims to elucidate the molecular mechanisms by which CDK9 regulates IPF, screen CDK9 inhibitors for anti-fibrotic efficacy, and develop an inhalable CDK9...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under CFDA 93.837 - Cardiovascular Diseases Research, provides $1,302,038 to the Regents of the University of Michigan to conduct research on targeting dysfunctional epithelial repair in pulmonary fibrosis. The research aims to elucidate the mediators and pathways that contribute to dysfunctional epithelial phenotypes in persistent lung fibrosis, determine the impact of hypoxia-inducible factor (HIF) signaling...
This Project Grant award of $5,715,866 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop novel, transformative therapies that substantially reduce the burden of morbidity and mortality from progressive pulmonary fibrosis (PF). The multi-year program, which began in September 2024, focuses on investigating the transcriptomic, genetic, epigenetic, metabolic, and environmental signatures that contribute to the initiation and early...